Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans

Rheumatology

Volumn 38, Issue 5, 1999, Pages 397-400

  Tager, R E ^a   Tikly, M ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Department of Medicine ^*  (South Africa)

Author keywords

Africa; Blacks; Scleroderma

Indexed keywords

ANTINUCLEAR ANTIBODY;

ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; CLINICAL FEATURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MYOSITIS; NEGRO; ONSET AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCLERODERMA; SEX DIFFERENCE; SOUTH AFRICA;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ENVIRONMENTAL EXPOSURE; FEMALE; GOLD; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MINING; MYOSITIS; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SCLERODERMA, SYSTEMIC; SOUTH AFRICA;

EID: 0032755423     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.5.397     Document Type: Article

References (30)

1. Silman AJ, Black CM, Welsh KI. Epidemiology, demographics, genetics. In: Clements PJ, Furst EF, eds. Systemic sclerosis. Maryland: Williams and Wilkins, 1996;23-44.
2. Medsger TA, Masi AT. The epidemiology of systemic sclerosis (scleroderma) among male US veterans. J Chron Dis 1978;31:73-85.
3. Somorin AO. Connective tissue diseases in Nigeria with emphasis on scleroderma. Cent Afr J Med 1980;26:59-63.
4. Erasmus LD. Scleroderma in gold-miners on the Witwatersrand with particular reference to pulmonary manifestations. S Afr J Lab Clin Med 1957;3:209-31.
5. Cowie RL, Dansey RD. Features of systemic sclerosis (scleroderma) in South African goldminers. S Afr Med J 1990;77:400-2.
6. Silber W. The prevalence, course and management of some benign oesophageal diseases in the black population. S Afr Med J 1983;63:957-9.
7. Pudifin DJ, Dinnematin H, Duursma J. Antinuclear antibodies in systemic sclerosis. S Afr Med J 1991;80:438-40.
8. Masi AT, Rodnan GP, Medsger TA Jr et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
9. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
10. Clements PJ. Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes. Curr Opin Rheumatol 1994;6:603-6.
11. von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24:323-58.
12. Sluis-Cremer GK, Hessel PA, Nizdo EH, Churchill AR, Zeiss EA. Silica, silicosis, and progressive systemic sclerosis. Br J Ind Med 1985;42:838-43.
13. Cowie RL. Silica-dust-exposed mine workers with scleroderma (systemic sclerosis). Chest 1987;92:260-2.
14. Daniel LN, Mao Y, Safiotti U. Oxidative DNA damage by crystalline silica. Free Rad Biol Med 1993;14:463-72.
15. Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalysed oxidation reactions: implications for pathogenesis. J Exp Med 1997;185:71-9.
16. Christy WC, Rodnan GP. Conjugal progressive systemic sclerosis (scleroderma): report of the disease in husband and wife. Arthritis Rheum 1984;27:1180-2.
17. Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 1989;28:281-6.
18. Jacobsen S, Halberg P, Ullman S, Van Venrooij WJ, Høier-Madsen M, Wiik A et al. Clinical and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1998;37:39-45.
19. Medsger TA, Steen V. Systemic sclerosis and related syndromes: clinical features and treatment. In: Schumacher RH, Klippel JH, Koopman WJ, eds. Primer on the rheumatic diseases, 10th edn. Atlanta: Arthritis Foundation, 1993:118-27.
20. Laing TJ, Gillespie BW, Toth MB, Mayes MD, Gallavan RH, Burns CJ et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997; 40:734-42.
21. Reveille JD, Durban E, Goldstein R, Moreda R, Arnett FC. Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1992;35:216-8.
22. Briggs DC, Vaughan RW, Welsh KI, Myers A, duBois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991;338:661-2.
23. Kane GC, Varga J, Conant et al. Lung involvement in systemic sclerosis (scleroderma): relationship to classification based on extent of skin involvement or autoantibody status. Respir Med 1996;90:223-30.
24. Sharp GC, Irvin WS, Tan EM et al. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148-59.
25. Misra R, Darton K, Jewkes RF, Black CM, Maini RN. Arthritis in scleroderma. Br J Rheumatol 1995;34:831-7.
26. Medsger TA, Steen VD. Classification, prognosis. In: Clements PJ, Furst EF, eds. Systemic sclerosis. Baltimore, MD: Williams and Wilkins, 1996:51-64.
27. Steen VD, Medsger TA, Osial TA, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984;76:779-86.
28. Sacks DG, Okano Y, Steen VD et al. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol 1996;23:639-42.
29. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994;37:75-83.
30. Briggs D, Stephens C, Vaughan R, Welsh K, Black C. A molecular and serologic analysis of the major histocompatibility complex and complement component C4 in systemic sclerosis. Arthritis Rheum 1993;36:943-54.